Gefitinib, Erlotinib, Lapatinib, Trametinib, Afatinib, and Osimertinib are tyrosine kinase inhibitors, that have been used in the treatment of non-small cell lung cancer and all of which target EGFR (Supplementary Table S4 and Supplementary Table S6). This evidence concerns the gene EGFR and non-small cell lung carcinoma.